ASH 2019: Ausblick auf Studien-Highlights beim follikulären Lymphom
Dr. Victor Rathkolb, 3. Medizinische Abteilung, Hanusch Krankenhaus Wien, berichtet im Gespräch mit medonline, welche Lymphom-Studien beim Jahreskongress der American Society of Hematology spannend werden. Darunter finden sich Ergebnisse zu Mosunetuzumab, Tazemetostat und dem 7-FLIPI-Score.
Quelle: ASH 2019 Annual Meeting
Abstracts, die im Video erwähnt werden:
Morschhauser F et al., Abstract 123
123 Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma
https://ash.confex.com/ash/2019/webprogram/Paper128096.html
Jurinovic V et al., Abstract 122
122 Evaluation of the m7-FLIPI in Patients with Follicular Lymphoma Treated within the Gallium Trial: EZH2 mutation Status May be a Predictive Marker for Differential Efficacy of Chemotherapy
https://ash.confex.com/ash/2019/webprogram/Paper130208.html
Pulsoni A et al., Abstract 124
124 EARLY STAGE Follicular Lymphoma: First Results of the FIL “Miro” Study, a Multicenter Phase II Trial Combining Local Radiotherapy and MRD-Driven Immunotherapy
https://ash.confex.com/ash/2019/webprogram/Paper123106.html